Tymlos 80 MCG dose pen injectr 1.56ML
Ended Awarded
- Contract number
- SPE2DB26FDQDR
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,335
Award facts
- Contract value 100% obligated
- $2,335.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,335.13 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for TYMLOS 80 MCG dose pen injectors (1.56ML). The award, issued on October 20, 2025, with an ultimate completion date of October 21, 2025, carries firm fixed-price terms and no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion acquisition strategy that positions multiple regional prime vendor contractors as critical pharmaceutical suppliers for Department of Defense healthcare operations worldwide.
DMS Pharmaceutical Group holds a prime vendor IDC under PPV-G GEN V with a $499.999 billion ceiling value and completion date of December 31, 2036, structured to support recurring medical supply needs of military healthcare facilities globally. The contractor has demonstrated substantial federal contracting activity through numerous delivery orders issued by the DLA's Medical Supply Chain division, supplying a comprehensive portfolio including branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables across multiple therapeutic categories. The company serves as a critical node within the federal pharmaceutical supply chain without identified subcontractors, leveraging its small business status and established performance record to fulfill the diverse and specialized pharmaceutical requirements of the Department of Defense military medical system.
Quick answers
Who was awarded contract SPE2DB26FDQDR?
SPE2DB26FDQDR was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 20, 2025.
How much is contract SPE2DB26FDQDR worth?
The government has obligated $2,335 on SPE2DB26FDQDR.
Is contract SPE2DB26FDQDR an order under another contract?
Yes. SPE2DB26FDQDR is a delivery order under SPE2DB24D9238, an indefinite delivery contract.
Was contract SPE2DB26FDQDR competed?
The extent of competition for SPE2DB26FDQDR was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award